BiotechTube
Coherence Neuro

Coherence Neuro

Pre-clinical
San Francisco, United StatesFounded 2022coherenceneuro.com

Coherence Neuro is a private, clinical-stage biotech founded in 2022, operating at the convergence of neurotechnology, neurobiology, and AI to treat cancer. The company's mission is to improve the length and quality of life for cancer patients by introducing a 'fourth pillar' of cancer therapy—bioelectronic modulation—alongside drugs, radiation, and surgery. Their lead program, SOMA, targets high-grade gliomas and has initiated its first safety study, with pipeline expansion into pancreatic cancer underway. Backed by a team of experts from Cambridge, Philips, Siemens, and Abbott, Coherence is building a platform with potential applications across numerous diseases influenced by the body's bioelectric code.

Market Cap
Private
Pipeline
—
Patents
—
Publications
—

Private Company

Total funding raised: $23M

AI Company Overview

Coherence Neuro is a private, clinical-stage biotech founded in 2022, operating at the convergence of neurotechnology, neurobiology, and AI to treat cancer. The company's mission is to improve the length and quality of life for cancer patients by introducing a 'fourth pillar' of cancer therapy—bioelectronic modulation—alongside drugs, radiation, and surgery. Their lead program, SOMA, targets high-grade gliomas and has initiated its first safety study, with pipeline expansion into pancreatic cancer underway. Backed by a team of experts from Cambridge, Philips, Siemens, and Abbott, Coherence is building a platform with potential applications across numerous diseases influenced by the body's bioelectric code.

OncologyNeurology

Technology Platform

A closed-loop therapeutic brain-computer interface (BCI) platform that reads the body's bioelectric signals and delivers targeted electrical stimulation to modulate disease, combining miniaturized implantable neurotechnology, cancer neuroscience, and AI-driven personalization.

Funding History

2
Total raised:$23M
Series A$20MMar 15, 2022
Seed$3MSep 15, 2020

Opportunities

Validating the SOMA platform in glioblastoma opens a path to treating numerous other solid tumors influenced by neural signaling (e.g., pancreatic, breast).
The core bioelectric code technology has disruptive potential beyond oncology in neurology, psychiatry, and immunology, representing a massive platform expansion opportunity.
Successful proof-of-concept could attract partnerships with large pharmaceutical or medtech companies seeking novel oncology modalities.

Risk Factors

The foundational science of using electricity to treat cancer is nascent and unproven in humans, posing a high biological risk.
As a first-of-its-kind implantable BCI for oncology, the company faces a complex and uncertain regulatory pathway with the FDA and other agencies.
Commercial adoption requires overcoming significant clinician skepticism and establishing reimbursement for a high-cost, surgically implanted device.

Competitive Landscape

Coherence faces limited direct competition in electro-oncology but competes with the entrenched standard of care (chemo/radiation/surgery). Adjacent competitors include neurostimulation companies like NeuroPace (epilepsy) and Setpoint/Roche (autoimmunity), which have similar technology but different indications. Coherence's differentiation lies in its exclusive cancer focus, AI-driven closed-loop system, and deep research into cancer neuroscience.